Hippocampal network alterations in Alzheimers Disease and down syndrome: From structure to therapy

Journal of Alzheimer's Disease

Volumn 26, Issue SUPPL. 3, 2011, Pages 29-47

  Sanchez, Martha Millan ^a,b   Moghadam, Sarah ^a   Naik, Priyanka ^a   Martin, Kara J ^a   Salehi, Ahmad ^a,b  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

Author keywords

Alzheimers disease; amyloid precursor protein; contextual learning; Down syndrome; L DOPS; locus coeruleus; norepinephrine; perforant path; xamoterol

Indexed keywords

AMYLOID BETA PROTEIN; AROMATIC LEVO AMINO ACID DECARBOXYLASE; CARBIDOPA; NORADRENALIN; THREO 3,4 DIHYDROXYPHENYLSERINE; XAMOTEROL;

AGING; ALZHEIMER DISEASE; ARTICLE; BRAIN FUNCTION; BRAIN REGION; CHROMOSOME 21; COGNITION; DEAFFERENTATION; DOWN SYNDROME; DRUG MECHANISM; HIPPOCAMPUS; HUMAN; LEARNING; LOCUS CERULEUS; MICROGLIA; MORPHOMETRICS; NERVE CELL PLASTICITY; NERVE DEGENERATION; NERVE PROJECTION; NEUROANATOMY; NONHUMAN; NORADRENERGIC NERVE; ORTHOSTATIC HYPOTENSION; PARKINSON DISEASE; PATHOLOGICAL ANATOMY; PATHOPHYSIOLOGY; PRIORITY JOURNAL; TRANSGENIC MOUSE;

EID: 80055034688     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-2011-0050     Document Type: Article

References (158)

1. Wisniewski KE, Wisniewski HM, Wen GY (1985) Occurrence of neuropathological changes and dementia of Alzheimers disease in Downs syndrome. Ann Neurol 17, 278-282. (Pubitemid 15136603)
2. Lai F,Williams RS (1989)Aprospective study of Alzheimer disease in Down syndrome. Arch Neurol 46, 849-853. (Pubitemid 19199367)
3. Chapman RS, Hesketh LJ (2000) Behavioral phenotype of individuals with Down syndrome. Ment Retard Dev Disabil Res Rev 6, 84-95. (Pubitemid 30399531)
4. Prasher VP, Farrer MJ, Kessling AM, Fisher EM, West RJ, Barber PC, Butler AC (1998) Molecular mapping of Alzheimer-type dementia in Downs syndrome. Ann Neurol 43, 380-383. (Pubitemid 28113601)
5. Roizen NJ, Patterson D (2003) Downs syndrome. Lancet 361, 1281-1289.
6. Salehi A. PB, Mobley WC. (2008) Down syndrome/ Trisomy 21. 2008. In The New Encyclopedia of Neuroscience Elsevier.
7. Chun MM, Jiang Y (2003) Implicit, long-term spatial contextual memory. J Exp Psychol Learn Mem Cogn 29, 224-234. (Pubitemid 38413918)
8. Lawrence JJ, McBain CJ (2003) Interneuron diversity series: containing the detonation-feedforward inhibition in the CA3 hippocampus. Trends Neurosci 26, 631-640. (Pubitemid 37338372)
9. Whitehouse PJ, Price DL, Struble RG, Clark AW, Coyle JT, Delon MR (1982) Alzheimers disease and senile dementia: loss of neurons in the basal forebrain. Science 215, 1237-1239. (Pubitemid 12106486)
10. Moudy AM, Kunkel DD, Schwartzkroin PA (1993) Development of dopamine-beta-hydroxylase-positive fiber innervation of the rat hippocampus. Synapse 15, 307-318.
11. Jacobs BL, Azmitia EC (1992) Structure and function of the brain serotonin system. Physiol Rev 72, 165-229.
12. Haglund L, Swanson LW, Kohler C (1984) The projection of the supramammillary nucleus to the hippocampal formation: an immunohistochemical and anterograde transport study with the lectin PHA-L in the rat. J Comp Neurol 229, 171-185. (Pubitemid 14007954)
13. Clarke DJ (1985) Cholinergic innervation of the rat dentate gyms: an immunocytochemical and electron microscopical study. Brain Res 360, 349-354. (Pubitemid 16171034)
14. FreundTF, AntalM(1988)GABA-containing neurons in the septum control inhibitory interneurons in the hippocampus. Nature 336, 170-173. (Pubitemid 18266144)
15. Kohler C, Chan-Palay V (1983) Distribution of gamma aminobutyric acid containing neurons and terminals in the septal area. an immunohistochemical study using antibodies to glutamic acid decarboxylase in the rat brain. Anat Embryol (Berl) 167, 53-65. (Pubitemid 13066777)
16. Amaral DG, Menno P.Witter. (1995) Hippocampal Formation In The Rat Nervous System, Paxinos G, ed. Academic Press.
17. Sara SJ (2009) The locus coeruleus and noradrenergic modulation of cognition. Nat Rev Neurosci 10, 211-223.
18. Tork I (1990) Anatomy of the serotonergic system. Ann N Y Acad Sci 600, 9-34; discussion 34-35.
19. Freund TF, Gulyas AI, Acsady L, Gores T, Toth K (1990) Serotonergic control of the hippocampus via local inhibitory interneurons. Proc Natl Acad Sci USA 87, 8501-8505.
20. Nitsch R, Leranth C (1993) Calretinin immunoreactivity in the monkey hippocampal formation-ii. Intrinsic GABAergic and hypothalamic non-GABAergic systems: an experimental tracing and co-existence study. Neuroscience 55, 797-812. (Pubitemid 23226122)
21. Mufson EJ, Kroin JS, Sendera TJ, Sobreviela T (1999) Distribution and retrograde transport of trophic factors in the central nervous system: functional implications for the treatment of neurodegenerative diseases. Prog Neurobiol 57, 451-484. (Pubitemid 29057112)
22. Celada P, Siuciak JA, Tran TM, Altar CA, Tepper JM (1996) Local infusion of brain-derived neurotrophic factor modifies the firing pattern of dorsal raphe serotonergic neurons. Brain Res 712, 293-298.
23. Friedman WJ, Ibanez CF, Hallbook F, Persson H, Cain LD, Dreyfus CF, Black IB (1993) Differential actions of neurotrophins in the locus coeruleus and basal forebrain. Exp Neurol 119, 72-78. (Pubitemid 23074243)
24. Sobreviela T, Pagcatipunan M, Kroin JS, Mufson EJ (1996) Retrograde transport of brain-derived neurotrophic factor (BDNF) following infusion in neo-and limbic cortex in rat: relationship to BDNF mRNA expressing neurons. J Comp Neurol 375, 417-444. (Pubitemid 26374782)
25. Braak H, Del Tredici K, Schultz C, Braak E (2000) Vulnerability of select neuronal types to Alzheimers disease. Ann N Y Acad Sci 924, 53-61. (Pubitemid 32050183)
26. Morys J, Sadowski M, Barcikowska M, Maciejewska B, Narkiewicz O (1994) The second layer neurones of the entorhinal cortex and the perforant path in physiological ageing and Alzheimers disease. Acta Neurobiol Exp (Wars) 54, 47-53. (Pubitemid 24113483)
27. Oliveira PP, Jr., Nitrini R, Busatto G, Buchpiguel C, Sato JR, Amaro E, Jr. (2010) Use of SVM methods with surface-based cortical and volumetric subcortical measurements to detect Alzheimers disease. JAlzheimers Dis 19, 1263-1272.
28. Abraham H, Vincze A, Jewgenow I, Veszpremi B, Kravjak A, Gomori E, Seress L (2010) Myelination in the human hippocampal formation from midgestation to adulthood. Int J Dev Neurosci 28, 401-410.
29. OdaY(1999) Choline acetyltransferase: the structure, distribution and pathologic changes in the central nervous system. Pathol Int 49, 921-937. (Pubitemid 30043131)
30. Aston-Jones G, Segal M, Bloom FE (1980) Brain aminergic axons exhibit marked variability in conduction velocity. Brain Res 195, 215-222. (Pubitemid 10077844)
31. Leranth C, Hajszan T (2007) Extrinsic afferent systems to the dentate gyms. Prog Brain Res 163, 63-84.
32. Shahidi S, Motamedi F, Naghdi N (2004) Effect of reversible inactivation of the supramammillary nucleus on spatial learning and memory in rats. Brain Res 1026, 267-274. (Pubitemid 39361556)
33. Moreau PH, Cosquer B, Jeltsch H, Cassel JC, Mathis C (2008) Neuroanatomical and behavioral effects of a novel version of the cholinergic immunotoxin mu p75-saporin in mice. Hippocampus 18, 610-622. (Pubitemid 351832748)
34. Borelli KG, Gargaro AC, dos Santos JM, Brandao ML (2005) Effects of inactivation of serotonergic neurons of the median raphe nucleus on learning and performance of contextual fear conditioning. Neurosci Lett 387, 105-110. (Pubitemid 41134207)
35. Compton DM, Dietrich KL, Smith JS, Davis BK (1995) Spatial and non-spatial learning in the rat following lesions to the nucleus locus coeruleus. Neuroreport 7, 177-182. (Pubitemid 26077221)
36. Mann DM (1985) The neuropathology of Alzheimers disease: a review with pathogenetic, aetiological and therapeutic considerations. Mech Ageing Dev 31, 213-255. (Pubitemid 16247953)
37. Amaral DG. (2010) Memory: Anatomical Organization of Candidate Brain Regions. In Comprehensive Physiology. Wiley, pp. 211-294.
38. Nakamura S, Takemura M, Ohnishi K, Suenaga T, Nishimura M, Akiguchi I, Kimura J, Kimura T (1993) Loss of large neurons and occurrence of neurofibrillary tangles in the tuberomammillary nucleus of patients with Alzheimers disease. Neurosci Lett 151, 196-199. (Pubitemid 23142359)
39. Salehi A, Heyn S, Gonatas NK,SwaabDF(1995) Decreased protein synthetic activity of the hypothalamic tuberomamillary nucleus in Alzheimers disease as suggested by smaller Golgi apparatus. Neurosci Lett 193, 29-32.
40. Schliebs R, Arendt T (2010) The cholinergic system in aging and neuronal degeneration. Behav Brain Res.
41. Mann DM, Yates PO, Marcyniuk B, Ravindra CR (1987) Loss of neurones from cortical and subcortical areas in Downs syndrome patients at middle age. Quantitative comparisons with younger Downs patients and patients with Alzheimers disease. J Neurol Sci 80, 79-89. (Pubitemid 17094627)
42. Hattori M, Fujiyama A, Taylor TD, Watanabe H, Yada T, Park HS, Toyoda A, Ishii K, Totoki Y, Choi DK, Groner Y, Soeda E, Ohki M, Takagi T, Sakaki Y, Taudien S, Blechschmidt K, Polley A, Menzel U, Delabar J, Kumpf K, Lehmann R, Patterson D, Reichwald K, Rump A, Schillhabel M, Schudy A, Zimmermann W, Rosenthal A, Kudoh J, Schibuya K, Kawasaki K, Asakawa S, Shintani A, Sasaki T, Nagamine K, Mitsuyama S, Antonarakis SE, Minoshima S, Shimizu N, Nordsiek G, Hornischer K, Brant P, Scharfe M, Schon O, Desario A, Reichelt J, Kauer G, Blocker H, Ramser J, Beck A, Klages S, Hennig S, Riesselmann L, Dagand E, Haaf T, Wehrmeyer S, Borzym K, Gardiner K, Nizetic D, Francis F, Lehrach H, Reinhardt R, Yaspo ML (2000) The DNA sequence of human chromosome 21 . Nature 405, 311-319. (Pubitemid 30337057)
43. Sturgeon X, Gardiner KJ (2011) Transcript catalogs of human chromosome 21 and orthologous chimpanzee and mouse regions. Mamm Genome.
44. Salehi A, Faizi M, Belichenko PV, MobleyWC(2007) Using mouse models to explore genotype-phenotype relationship in Down syndrome. Merit Retard Dev Disabil Res Rev 13, 207-214. (Pubitemid 47613274)
45. Bekris LM, Yu CE, Bird TD, Tsuang DW (2010) Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol 23, 213-227.
46. Salehi A, Delcroix JD, Belichenko PV, Zhan K, Wu C, Valletta JS, Takimoto-Kimura R, Kleschevnikov AM, Sambamurti K, Chung PP, Xia W, Villar A, Campbell WA, Kulnane LS, Nixon RA, Lamb BT, Epstein CJ, Stokin GB, Goldstein LS, MobleyWC(2006) Increased App expression in a mouse model of Downs syndrome disrupts NGF transport and causes cholinergic neuron degeneration. Neuron 51, 29-42. (Pubitemid 43963336)
47. Bullido MJ, Ramos MC, Ruiz-Gomez A, Tutor AS, Sastre I, Frank A, Coria F, Gil P, Mayor F, Valdivieso F (2004) Polymorphism in genes involved in adrenergic signaling associated with Alzheimers. Neurobiol Aging 25, 853-859. (Pubitemid 38813165)
48. Dahlstroem A, FuxeK(1964)EVIDENCEFORTHEEXISTENCE OF MONOAMINE-CONTAINING NEURONS IN THE CENTRAL NERVOUS SYSTEM. i. demonstration of monoamines in the cell bodies of brain stem neurons. Ada Physiol Scand Suppl (232), 231-255.
49. Berridge CW, Waterhouse BD (2003) The locus coeruleusnoradrenergic system: modulation of behavioral state and state-dependent cognitive processes. Brain Res Brain Res Rev 42, 33-84. (Pubitemid 36369264)
50. Mouton PR, Pakkenberg B, Gundersen HJ, Price DL (1994) Absolute number and size of pigmented locus coeruleus neurons in young and aged individuals. J Chem Neuroanat 7, 185-190. (Pubitemid 24310337)
51. Palmer AM, DeKosky ST (1993) Monoamine neurons in aging and Alzheimers disease. J Neural Transm Gen Sect 91, 135-159. (Pubitemid 23131301)
52. Jones BE, Yang TZ (1985) The efferent projections from the reticular formation and the locus coeruleus studied by anterograde and retrograde axonal transport in the rat. J Comp Neurol 242, 56-92. (Pubitemid 16202793)
53. Foote SL, Morrison JH (1987) Extrathalamic modulation of cortical function. Annu Rev Neurosci 10, 67-95. (Pubitemid 17022769)
54. Zaborszky L, Cullinan WE, Luine VN (1993) Catecholaminergic-cholinergic interaction in the basal forebrain. Prog Brain Res 98, 31-49. (Pubitemid 23305628)
55. Loy R, Koziell DA, Lindsey JD, Moore RY (1980) Noradrenergic innervation of the adult rat hippocampal formation. J Comp Neurol 189, 699-710. (Pubitemid 10105678)
56. Aston-Jones G, Ennis M, PieriboneVA, NickellWT, Shipley MT (1986) The brain nucleus locus coeruleus: restricted afferent control of a broad efferent network. Science 234, 734-737. (Pubitemid 17184220)
57. Ennis M, Aston-Jones G (1988) Activation of locus coeruleus from nucleus paragigantocellularis: a new excitatory amino acid pathway in brain. J Neurosci 8, 3644-3657.
58. Ennis M, Aston-Jones G (1989) Potent inhibitory input to locus coeruleus from the nucleus prepositus hypoglossi. Brain Res Bull 22, 793-803. (Pubitemid 19196359)
59. Ennis M, Aston-Jones G (1989) GABA-mediated inhibition of locus coeruleus from the dorsomedial rostral medulla. J Neurosci 9, 2973-2981. (Pubitemid 19214328)
60. Gaymard B, Pierrot-Deseilligny C (1999) Neurology of saccades and smooth pursuit. Curr Opin Neurol 12, 13-19. (Pubitemid 29097553)
61. Van Bockstaele EJ, Aston-Jones G (1995) Integration in the ventral medulla and coordination of sympathetic, pain and arousal functions. Clin Exp Hypertens 17, 153-165.
62. Aston-Jones G, Shipley MT, Chouvet G, Ennis M, van Bockstaele E, Pieribone V, Shiekhattar R, Akaoka H, Drolet G, Astier B, et al.(1991) Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res 88, 47-75.
63. Murchison CF, Zhang XY, Zhang WP, Ouyang M, Lee A, Thomas SA (2004) A distinct role for norepinephrine in memory retrieval. Cell 117, 131-143. (Pubitemid 38469904)
64. Herrmann N, Lanctot KL, Khan LR (2004) The role of norepinephrine in the behavioral and psychological symptoms of dementia. J Neuropsychiatry Clin Neurosci 16, 261-276. (Pubitemid 39244552)
65. Amara SG, Kuhar MJ (1993) Neurotransmitter transporters: recent progress. Anna Rev Neurosci 16, 73-93. (Pubitemid 23074001)
66. Benarroch EE (2009) The locus ceruleus norepinephrine system: functional organization and potential clinical significance. Neurology 73, 1699-1704.
67. Gilsbach R, Hein L (2008) Presynaptic metabotropic receptors for acetylcholine and adrenaline/noradrenaline. Handb Exp Pharmacol, 261-288.
68. Duncan GE, Little KY, Koplas PA, Kirkman JA, Breese GR, Stumpf WE (1991) Beta-adrenergic receptor distribution in human and rat hippocampal formation: marked species differences. Brain Res 561, 84-92.
69. Starke K (2001) Presynaptic autoreceptors in the third decade: focus on alpha2-adrenoceptors. J Neurochem 78, 685-693. (Pubitemid 32777970)
70. Arnsten AF, Steere JC, Hunt RD (1996) The contribution of alpha 2-noradrenergic mechanisms of prefrontal cortical cognitive function. Potential significance for attentiondeficit hyperactivity disorder. Arch Gen Psychiatry 53, 448-455. (Pubitemid 26149234)
71. Nestler EJ, Alreja M, AghajanianGK(1999) Molecular control of locus coeruleus neurotransmission. Biol Psychiatry 46, 1131-1139. (Pubitemid 30114432)
72. Devauges V, Sara SJ (1991) Memory retrieval enhancement by locus coeruleus stimulation: evidence for mediation by beta-receptors. Behav Brain Res 43, 93-97.
73. Ji JZ,Wang XM, Li BM(2003) Deficit in long-term contextual fear memory induced by blockade of beta-adrenoceptors in hippocampal CA1 region. Eur J Neurosci 17, 1947-1952.
74. Ji JZ, Zhang XH, Li BM (2003) Deficient spatial memory induced by blockade of beta-adrenoceptors in the hippocampal CA1 region. Behav Neurosci 117, 1378-1384.
75. Juric DM, Miklic S, Carman-Krzan M (2006) Monoaminergic neuronal activity up-regulates BDNF synthesis in cultured neonatal rat astrocytes. Brain Res 1108, 54-62. (Pubitemid 44278004)
76. Juric DM, Loncar D, Carman-Krzan M (2008) Noradrenergic stimulation of BDNF synthesis in astrocytes: mediation via alphai-and betai/beta2-adrenergic receptors. Neurochem Int 52, 297-306. (Pubitemid 350235707)
77. Nagahara AH, Merrill DA, Coppola G, Tsukada S, Schroeder BE, Shaked GM, Wang L, Blesch A, Kim A, Conner JM, Rockenstein E, Chao MV, Koo EH, Geschwind D, Masliah E, Chiba AA, Tuszynski MH (2009) Neuroprotective effects of brain-derived neurotrophic factor in rodent and primate models of Alzheimers disease. Nat Med 15, 331-337.
78. Bondareff W, Mountjoy CQ, Roth M (1982) Loss of neurons of origin of the adrenergic projection to cerebral cortex (nucleus locus ceruleus) in senile dementia. Neurology 32, 164-168. (Pubitemid 12223999)
79. Mitchell HA, Weinshenker D. Good night and good luck: norepinephrine in sleep pharmacology. Biochem Pharmacol 79, 801-809.
80. Aston-Jones G, Bloom FE (1981) Norepinephrinecontaining locus coeruleus neurons in behaving rats exhibit pronounced responses to non-noxious environmental stimuli. J Neurosci 1, 887-900. (Pubitemid 11025877)
81. Minzenberg MJ, Watrous AJ, Yoon JH, Ursu S, Carter CS (2008) Modafinil shifts human locus coeruleus to low-tonic, high-phasic activity during functional mri. Science 322, 1700-1702.
82. Bliwise DL (2004) Sleep disorders in Alzheimers disease and other dementias. Clin Cornerstone 6(Suppl 1A), 16-28.
83. Maurizi CP (1987) Dementia-the failure of hippocampal plasticity and dreams. Is there a preventative role for melatonin? Med Hypotheses 24, 59-68. (Pubitemid 18022644)
84. Khakpour-Taleghani B, Lashgari R, Motamedi F, Naghdi N (2009) Effect of reversible inactivation of locus ceruleus on spatial reference and working memory. Neuroscience 158, 1284-1291.
85. van Stegeren AH (2008) The role of the noradrenergic system in emotional memory. Acta Psychol (Amst) 127, 532-541.
86. Rodrigues SM, LeDoux JE, Sapolsky RM(2009) The influence of stress hormones on fear circuitry. Annu Rev Neurosci 32, 289-313.
87. Sterpenich V, DArgembeau A, Desseilles M, Balteau E, Albouy G, Vandewalle G, Degueldre C, Luxen A, Collette F, Maquet P (2006) The locus ceruleus is involved in the successful retrieval of emotional memories in humans. J Neurosci 26, 7416-7423. (Pubitemid 44315210)
88. Tully K, Bolshakov VY (Brain) Emotional enhancement of memory: how norepinephrine enables synaptic plasticity. Mol 3, 15.
89. Hu H, Real E, Takamiya K, Kang MG, Ledoux J, Huganir RL, MalinowR (2007) Emotion enhances learning via norepinephrine regulation of AMPA-receptor trafficking. Cell 131, 160-173. (Pubitemid 47498536)
90. Ikegaya Y, Nakanishi K, Saito H, Abe K (1997) Amygdala beta-noradrenergic influence on hippocampal long-term potentiation in vivo. Neuroreport 8, 3143-3146. (Pubitemid 27421747)
91. Harley CW (2007) Norepinephrine and the dentate gyms. Prog Brain Res 163, 299-318.
92. Crowe SF, Shaw S (1997) Salbutamol overcomes the effect of the noradrenergic neurotoxin DSP-4 on memory function in the day-old chick. Behav Pharmacol 8, 216-222. (Pubitemid 27303916)
93. Gibbs ME,Maksel D, Gibbs Z, Hou X, Summers RJ, Small DH. Memory loss caused by beta-amyloid protein is rescued by a beta(3)-adrenoceptor agonist. Neurobiol Aging 31, 614-624.
94. Salehi A, Faizi M, Colas D, Valletta J, Laguna J, Takimoto-Kimura R, Kleschevnikov A,Wagner SL, Aisen P, Shamloo M, Mobley WC (2009) Restoration of norepinephrinemodulated contextual memory in a mouse model of Down syndrome. Sci Transl Med 1, 7ra17.
95. Gliebus G, Lippa CF (2007) The influence of beta-blockers on delayed memory function in people with cognitive impairment. Am J Alzheimers Dis Other Demen 22, 57-61. (Pubitemid 46339252)
96. Cahill L, Prins B, Weber M, McGaugh JL (1994) Betaadrenergic activation and memory for emotional events. Nature 371, 702-704.
97. Siniscalchi A, Badini I, Bianchi C, Beani L (1994) Monoamines modulate the electrically-evoked efflux of 3Hcholine from slices of guinea pig nucleus basalis magnocellularis. Naunyn Schmiedebergs Arch Pharmacol 350, 10-14. (Pubitemid 24214242)
98. Tellez S, Colpaert F, MarienM(1999) Alpha2-adrenoceptor modulation of cortical acetylcholine release in vivo. Neuroscience 89, 1041-1050. (Pubitemid 29074624)
99. Arnsten AF, Goldman-Rakic PS (1985) Alpha 2-adrenergic mechanisms in prefrontal cortex associated with cognitive decline in aged nonhuman primates. Science 230, 1273-1276. (Pubitemid 16194533)
100. Lockrow J, Boger H, Gerhardt G, Bachman D, Granholm AC. A Noradrenergic Lesion Exacerbates Neurodegeneration in a Down syndrome Mouse Model. J Alzheimers Dis.
101. Peskind ER, Elrod R, Dobie DJ, PascualyM,Petrie E, Jensen C, Brodkin K, Murray S, Veith RC, Raskind MA (1998) Cerebrospinal fluid epinephrine in Alzheimers disease and normal aging. Neuropsychopharmacology 19, 465-471. (Pubitemid 28491372)
102. Bierer LM, Aisen PS, Davidson M, Ryan TM, Stern RG, Schmeidler J, Davis KL (1993) A pilot study of oral physostigmine plus yohimbine in patients with Alzheimer disease. Alzheimer Dis Assoc Disord 7, 98-104. (Pubitemid 23222512)
103. Davis JA, Gould TJ (2007) Atomoxetine reverses nicotine withdrawal-associated deficits in contextual fear conditioning. Neuropsychopharmacology 32, 2011-2019. (Pubitemid 47258511)
104. Murchison CF, Schutsky K, Jin SH, Thomas SA (2011) Norepinephrine and betai-adrenergic signaling facilitate activation of hippocampal cai pyramidal neurons during contextual memory retrieval. Neuroscience.
105. Olson VG, Rockett HR, Reh RK, Redila VA, Tran PM, Venkov HA, Defino MC, Hague C, Peskind ER, Szot P, Raskind MA (2011) The role of norepinephrine in differential response to stress in an animal model of posttraumatic stress disorder. Biol Psychiatry,Teaching and learning (ii). howadults learn. Nurs Times 89, i-viii.
106. Witter MP, Naber PA, van Haeften T, Machielsen WC, Rombouts SA, Barkhof F, Scheltens P, Lopes da Silva FH (2000) Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways. Hippocampus 10, 398-410.
107. BecksteadRM(1978) Afferent connections of the entorhinal area in the rat as demonstrated by retrograde cell-labeling with horseradish peroxidase. Brain Res 152, 249-264. (Pubitemid 9134490)
108. Dolorfo CL, Amaral DG (1998) Entorhinal cortex of the rat: topographic organization of the cells of origin of the perforant path projection to the dentate gyrus. J Comp Neurol 398, 25-48. (Pubitemid 28373875)
109. Kerr KM, Agster KL, Furtak SC, Burwell RD (2007) Functional neuroanatomy of the parahippocampal region: the lateral and medial entorhinal areas. Hippocampus 17, 697-708. (Pubitemid 47493452)
110. Hafting T, Fyhn M, Molden S, Moser MB,Moser EI (2005) Microstructure of a spatial map in the entorhinal cortex. Nature 436, 801-806. (Pubitemid 41160632)
111. Steffenach HA,Witter M, Moser MB, Moser EI (2005) Spatial memory in the rat requires the dorsolateral band of the entorhinal cortex. Neuron 45, 301-313. (Pubitemid 40128123)
112. Harley CH. (2007) norepinephrine and the dentate gyrus In Progress in Brain Research, Scharfman HE, ed. Elsevier.
113. Lacaille JC, HarleyCW(1985) The action of norepinephrine in the dentate gyrus: beta-mediated facilitation of evoked potentials in vitro. Brain Res 358, 210-220. (Pubitemid 16184091)
114. Stanton PK, Sarvey JM (1985) Blockade of norepinephrineinduced long-lasting potentiation in the hippocampal dentate gyrus by an inhibitor of protein synthesis. Brain Res 361, 276-283. (Pubitemid 16185364)
115. Dahl D, Sarvey JM (1989) Norepinephrine induces pathway-specific long-lasting potentiation and depression in the hippocampal dentate gyrus. Proc Natl Acad Sci USA 86, 4776-4780. (Pubitemid 19164632)
116. Papastavrou E, Kalokerinou A, Papacostas SS, Tsangari H, Sourtzi P (2007) Caring for a relative with dementia: family caregiver burden. J Adv Nurs 58, 446-457.
117. Gaugler JE, Yu F, Krichbaum K, Wyman JF (2009) Predictors of nursing home admission for persons with dementia. Med Care 47, 191-198.
118. Palmer AM, Francis PT, Bowen DM, Benton JS, Neary D, Mann DM, Snowden JS (1987) Catecholaminergic neurones assessed ante-mortem in Alzheimers disease. Brain Res 414, 365-375. (Pubitemid 17091962)
119. Grudzien A, Shaw P, Weintraub S, Bigio E, Mash DC, Mesulam MM (2007) Locus coeruleus neurofibrillary degeneration in aging, mild cognitive impairment and early Alzheimers disease. Neurobiol Aging 28, 327-335. (Pubitemid 46178530)
120. German DC, Manaye KF, White CL, Woodward DJ, Mclntire DD, Smith WK, Kalaria RN, Mann DM (1992) Disease-specific patterns of locus coeruleus cell loss. Ann Neurol 32, 667-676.
121. Cole G, Neal JW, Singhrao SK, Jasani B, Newman GR (1993) The distribution of amyloid plaques in the cerebellum and brain stem in Downs syndrome and Alzheimers disease: a light microscopical analysis. Ada Neuropathol 85, 542-552. (Pubitemid 23180418)
122. Hoogendijk WJ, Pool CW, Troost D, van Zwieten E, Swaab DF (1995) Image analyser-assisted morphometry of the locus coeruleus in Alzheimers disease, Parkinsons disease and amyotrophic lateral sclerosis. Brain 118(1), 131-143.
123. Iversen LL, Rossor MN, Reynolds GP, Hills R, Roth M, Mountjoy CQ, Foote SL, Morrison JH, Bloom FE (1983) Loss of pigmented dopamine-beta-hydroxylase positive cells from locus coeruleus in senile dementia of Alzheimers type. Neurosci Lett 39, 95-100. (Pubitemid 13039214)
124. Matthews KL, Chen CP, Esiri MM, Keene J, Minger SL, Francis PT (2002) Noradrenergic changes, aggressive behavior, and cognition in patients with dementia. Biol Psychiatry 51, 407-416. (Pubitemid 34251178)
125. Szot P, White SS, Greenup JL, Leverenz JB, Peskind ER, Raskind MA (2006) Compensatory changes in the noradrenergic nervous system in the locus ceruleus and hippocampus of postmortem subjects with Alzheimers disease and dementia with lewy bodies. J Neurosci 26, 467-478. (Pubitemid 43237111)
126. Zarow C, Lyness SA, Mortimer JA, Chui HC (2003) Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and parkinson diseases. Arch Neurol 60, 337-341. (Pubitemid 36314358)
127. Hoogendijk WJ, Feenstra MG, Botterblom MH, Gilhuis J, Sommer IE, Kamphorst W, Eikelenboom P, Swaab DF (1999) Increased activity of surviving locus ceruleus neurons in Alzheimers disease. Ann Neurol 45, 82-91. (Pubitemid 29036436)
128. Kalinin S, Gavrilyuk V, Polak PE, Vasser R, Zhao J, Heneka MT, Feinstein DL (Aging) (2007) Noradrenaline deficiency in brain increases beta-amyloid plaque burden in an animal model of Alzheimers disease. Neurobiol 28, 1206-1214. (Pubitemid 46810064)
129. ONeil JN, Mouton PR, Tizabi Y, Ottinger MA, Lei DL, Ingram DK, Manaye KF (2007) Catecholaminergic neuronal loss in locus coeruleus of aged female dtg APP/PS1 mice. J Chem Neuroanat 34, 102-107. (Pubitemid 47333071)
130. Heneka MT, Ramanathan M, Jacobs AH, Dumitrescu-Ozimek L, Bilkei-Gorzo A, Debeir T, Sastre M, Galldiks N, Zimmer A, Hoehn M, HeissWD,KlockgetherT, Staufenbiel M(2006) Locus ceruleus degeneration promotes Alzheimer pathogenesis in amyloid precursor protein 23 transgenic mice. J Neurosci 26, 1343-1354. (Pubitemid 43237005)
131. Jardanhazi-Kurutz D, Kummer MP, Terwel D, Vogel K, Dyrks T, Thiele A, Heneka MT. Induced LC degeneration in APP/PSi transgenic mice accelerates early cerebral amyloidosis and cognitive deficits. Neurochem Int 57, 375-382.
132. Heneka MT, Galea E, Gavriluyk V, Dumitrescu-Ozimek L, Daeschner J, OBanion MK, Weinberg G, Klockgether T, Feinstein DL (2002) Noradrenergic depletion potentiates beta -amyloid-induced cortical inflammation: implications for Alzheimers disease. J Neurosci 22, 2434-2442. (Pubitemid 37465791)
133. Heneka MT, Nadrigny F, Regen T, Martinez-Hernandez A, Dumitrescu-Ozimek L, Terwel D, Jardanhazi-Kurutz D, Walter J, Kirchhoff F, Hanisch UK, Kummer MP. Locus ceruleus controls Alzheimers disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci USA 107, 6058-6063.
134. Tanaka KF, Kashima H, Suzuki H, Ono K, SawadaM(2002) Existence of functional beta1-and beta2-adrenergic receptors on microglia. J Neurosci Res 70, 232-237.
135. KongY, Ruan L, Qian L, Liu X, LeY(2010) Norepinephrine promotes microglia to uptake and degrade amyloid beta peptide through upregulation of mouse formyl peptide receptor and induction of insulin-degrading enzyme. J Neurosci 30, 11848-11857.
136. Reeves TM, Lyeth BG, Povlishock JT (1995) Long-term potentiation deficits and excitability changes following traumatic brain injury. Exp Brain Res 106, 248-256.
137. EscorihuelaRM,Fernandez-Teruel A,Vallina IF, Baamonde C, Lumbreras MA, Dierssen M, Tobena A, Florez J (1995) A behavioral assessment of Ts65Dn mice: a putative Down syndrome model. Neurosci Lett 199, 143-146.
138. Escorihuela RM, Vallina IF,Martinez-Cue C, Baamonde C, Dierssen M, Tobena A, Florez J, Fernandez-Teruel A (1998) Impaired short-and long-term memory in Ts65Dn mice, a model for Down syndrome. Neurosci Lett 247, 171-174. (Pubitemid 28240124)
139. Demas GE, Nelson RJ, Krueger BK, Yarowsky PJ (1998) Impaired spatial working and reference memory in segmental trisomy (Ts65Dn) mice. Behau Brain Res 90, 199-201. (Pubitemid 28080561)
140. Sago H, Carlson EJ, Smith DJ, Rubin EM, Crnic LS, Huang TT, Epstein CJ (2000) Genetic dissection of region associated with behavioral abnormalities in mouse models for Down syndrome. Pediatr Res 48, 606-613.
141. Hyde LA, Frisone DF, Crnic LS (2001) Ts65Dn mice, a model for Down syndrome, have deficits in context discrimination learning suggesting impaired hippocampal function. Behau Brain Res 118, 53-60. (Pubitemid 32037113)
142. Belichenko PV, Masliah E, Kleschevnikov AM, Villar AJ, Epstein CJ, Salehi A, Mobley WC (2004) Synaptic structural abnormalities in the Ts65Dn mouse model of Down Syndrome. J Comp Neurol 480, 281-298. (Pubitemid 39578025)
143. Siarey RJ, Carlson EJ, Epstein CJ, Balbo A, Rapoport SI, Galdzicki Z (1999) Increased synaptic depression in the Ts65Dn mouse, a model for mental retardation in Down syndrome. Neuropharmacology 38, 1917-1920. (Pubitemid 29509730)
144. Kleschevnikov AM, Belichenko PV, Villar AJ, Epstein CJ, Malenka RC, Mobley WC (2004) Hippocampal longterm potentiation suppressed by increased inhibition in the Ts65Dn mouse, a genetic model of Down syndrome. J Neurosci 24, 8153-8160. (Pubitemid 39280835)
145. Holtzman DM, Santucci D, Kilbridge J, Chua-Couzens J, Fontana DJ, Daniels SE, Johnson RM, Chen K, Sun Y, Carlson E, Alleva E, Epstein CJ, MobleyWC (1996) Developmental abnormalities and age-related neurodegeneration in a mouse model of Down syndrome. Proc Natl Acad Sci USA 93, 13333-13338. (Pubitemid 26382816)
146. Dierssen M, Vallina IF, Baamonde C, Garcia-Calatayud S, Lumbreras MA, Florez J (1997) Alterations of central noradrenergic transmission in Ts65Dn mouse, a model for Down syndrome. Brain Res 749, 238-244. (Pubitemid 27104205)
147. GranholmAC, Sanders LA, Crnic LS (2000) Loss of cholinergic phenotype in basal forebrain coincides with cognitive decline in a mouse model of Downs syndrome. Exp Neurol 161, 647-663. (Pubitemid 30137022)
148. Cooper JD, Salehi A, Delcroix JD, Howe CL, Belichenko PV, Chua-Couzens J, Kilbridge JF, Carlson EJ, Epstein CJ, Mobley WC (2001) Failed retrograde transport of ngf in a mouse model of Downs syndrome: reversal of cholinergic neurodegenerative pheno types following NGF infusion. Proc Natl Acad Sci USA 98, 10439-10444. (Pubitemid 32803038)
149. Salehi A, Lucassen PJ, Pool CW, Gonatas NK, Ravid R, Swaab DF (1994) Decreased neuronal activity in the nucleus basalis of meynert in Alzheimers disease as suggested by the size of the Golgi apparatus. Neuroscience 59, 871-880. (Pubitemid 24149097)
150. SofroniewMV,Howe CL, MobleyWC(2001) Nerve growth factor signaling, neuroprotection, and neural repair. Annu Rev Neurosci 24, 1217-1281. (Pubitemid 32695259)
151. PoonWW, Blurton-Jones M, Tu CH, Feinberg LM, Chabrier MA, Harris JW, Jeon NL, CotmanCW(2009) Beta-amyloid impairs axonal BDNF retrograde trafficking. Neurobiol Aging.
152. Weil-Malherbe H, Whitby LG, Axelrod J (1961) The uptake of circulating 3Hnorepinephrine by the pituitary gland and various areas of the brain. J Neurochem 8, 55-64.
153. Kato T, Karai N, Katsuyama M, Nakamura M, Katsube J (1987) Studies on the
154. GoldsteinDS(2006) L-dihydroxyphenylserine (L-DOPS): a norepinephrine prodrug. Cardiovasc Drug Rev 24, 189-203. (Pubitemid 46435002)
155. Kaufmann H (2006) The discovery of the pressor effect of DOPS and its blunting by decarboxylase inhibitors. J Neural Transm Suppl, 477-484. (Pubitemid 44622240)
156. Russo-Neustadt A, Cotman CW (1997) Adrenergic receptors in Alzheimers disease brain: selective increases in the cerebella of aggressive patients. J Neurosci 17, 5573-5580. (Pubitemid 27300321)
157. Peskind ER, Wingerson D, Murray S, Pascualy M, Dobie DJ, Le Corre P, Le Verge R, Veith RC, Raskind MA (1995) Effects of Alzheimers disease and normal aging on cerebrospinal fluid norepinephrine responses to yohimbine and clonidine. Arch Gen Psychiatry 52, 774-782.
158. Liu Y, Yoo MJ, Savonenko A, Stirling W, Price DL, Borchelt DR, Mamounas L, Lyons WE, Blue ME, Lee MK (2008) Amyloid pathology is associated with progressive monoaminergic neurodegeneration in a transgenic mouse model of Alzheimers disease. J Neurosci 28, 13805-13814.